Coronavirus company news summary – Turkmenistan approves Sputnik V vaccine – Pakistan approves its second Covid-19 vaccine developed by Sinopharm

19 January 2021 (Last Updated January 19th, 2021 08:55)

19 January 2021

Spanish pharma company Grifols will commence a clinical trial to evaluate the safety and effectiveness of a new Covid-19 drug, which will hopefully provide immediate immunity against the SARS-CoV-2 virus. This treatment is based on Grifols’ immunoglobulin Gamunex®-C, which also contains anti-SARS-CoV-2 polyclonal antibodies from plasma donors.

Switzerland-based Debiopharm is carrying out its first patient dose investigator, randomised Phase II, open-label clinical trial for its antiviral oral drug Alisporivir (Debio 025). The Hospital of Paris will be conducting the study, which will evaluate the use of the cyclophilin inhibitor for treating early stage, hospitalised Covid-19 patients.

The Drug Regulatory Authority Pakistan has granted emergency use authorisation to  Chinese Sinopharm’s Covid-19 vaccine in Pakistan.  This comes two days after the country approved the use of the AstraZeneca/University of Oxford vaccine.

According to the Ministry of Health and Medical Industry of Turkmenistan, the Russian Direct Investment Fund has registered its Sputnik V vaccine to prevent Covid-19 in the country. The vaccine received emergency use authorisation without the need for additional trials to be conducted in Turkmenistan.